ZFIN ID: ZDB-FIG-170908-42
Mathews et al., 2016 - Cholesterol Biosynthesis Supports Myelin Gene Expression and Axon Ensheathment through Modulation of P13K/Akt/mTor Signaling. The Journal of neuroscience : the official journal of the Society for Neuroscience   36:7628-39 Full text @ J. Neurosci.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Fish:
Conditions:
Knockdown Reagents:
Anatomical Terms:
Stage: Day 4
PHENOTYPE:
Fish:
Conditions:
Knockdown Reagents:
Observed In:
Stage: Day 4

Fig. 6 ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Gene Expression Details
Gene Antibody Fish Conditions Stage Qualifier Anatomy Assay
EGFP hmgcs1vu57/vu57; vu16Tg control Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol, chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol, chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 control Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 control Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 Not Detected oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg control Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg + MO4-tp53 control Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg + MO4-tp53 chemical treatment by environment: sirolimus Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
vu16Tg + MO4-tp53 chemical treatment by environment: U0126 Day 4 oligodendrocyte glial cell projection IFL
Day 4 oligodendrocyte myelin sheath IFL
Day 4 spinal cord oligodendrocyte IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
hmgcs1vu57/vu57; vu16Tg control Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol, chemical treatment by environment: sirolimus Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol, chemical treatment by environment: U0126 Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg chemical treatment by injection: cholesterol Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg chemical treatment by environment: sirolimus Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
hmgcs1vu57/vu57; vu16Tg chemical treatment by environment: U0126 Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 control Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 spinal cord central nervous system myelination occurrence, ameliorated
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 control Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 chemical treatment by environment: sirolimus Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
hmgcs1vu57/vu57; vu16Tg + MO4-tp53 chemical treatment by environment: U0126 Day 4 spinal cord central nervous system myelination decreased occurrence, abnormal
vu16Tg + MO4-tp53 control Day 4 spinal cord central nervous system myelination occurrence, normal
vu16Tg + MO4-tp53 chemical treatment by environment: sirolimus Day 4 spinal cord central nervous system myelination occurrence, normal
vu16Tg + MO4-tp53 chemical treatment by environment: U0126 Day 4 spinal cord central nervous system myelination occurrence, normal
Full text @ J. Neurosci.